Cortex Pharmaceuticals Inc. and privately held Pier Pharmaceuticals Inc. completed an all-stock merger, adding a Phase II-ready obstructive sleep apnea compound to a pipeline now focused exclusively on brain-controlled sleeping disorders. Rebranding Cortex in the sleep apnea market, which has no pharmaceutical options, could create a biotech with greater value than the sum of its parts.